Molecular Vision 2011; 17:2139-2147
Received 28 December 2010 | Accepted 3 August 2011 | Published 11 August 2011
Xiaohui Zhang, Panfeng Wang, Shiqiang Li, Xueshan Xiao, Xiangming Guo, Qingjiong Zhang
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China
Correspondence to: Dr. Qingjiong Zhang, Ophthalmic Genetics & Molecular Biology, Zhongshan Ophthalmic Center, Sun Yat-sen University 54 Xianlie Road, Guangzhou 510060, China; Phone: (+86)-20-87330422; FAX: (+86)-20-87333271; email: firstname.lastname@example.org or email@example.com
Purpose: To identify mutations in the paired box 6 (PAX6) gene of 33 probands with aniridia and to reveal the mutational spectrum in the Chinese population.
Methods: Unrelated probands with aniridia from 27 newly selected families and six previously analyzed families participated in this study. The coding regions of PAX6 in the 27 new families were analyzed using cycle sequencing. Families that lacked detectable variations based on sequencing (14 new and six previously analyzed) were further analyzed using multiplex ligation-dependent probe amplification (MLPA).
Results: Fifteen mutations were identified in 16 of the 33 families: c.[65_94del30; 99_105dup7], c.101_102insA, c.177delG, c.238_239insGCGA, c.1033–42_1033–26del17insG, c.1A>G, c.120C>A, c.718C>T, c.949C>T, c.1062C>A, c.1183G>A, c.1268A>T, and three gross deletions involving exons 1–14, exons 8–14, and exons 9–14. The first five mutations were novel and the c.1268A>T mutation was present in two families. Phenotypic variations were observed between families and between different affected patients within the families.
Conclusions: The PAX6 mutation spectrum in Chinese aniridia patients is comparable to that reported in other ethnic groups. Further studies of the 17 families with no detected mutations may provide additional information to improve the understanding of the molecular genetics of aniridia.
Aniridia (OMIM 106210) is a bilateral, panocular disorder characterized by the absence of the iris. It is usually accompanied by developmental defects of the cornea, lens, retina, optic nerve, and/or the anterior chamber angle . Approximately two thirds of all cases are transmitted as an autosomal dominant trait among families. The remaining one third are sporadic, with no family history [1-3]. Mutations in PAX6 (OMIM 607108) have been shown to be responsible for aniridia in most patients [4-10]. In rare cases, PAX6 mutations may cause other ocular abnormalities, such as cataracts , Peters anomaly [12,13], foveal dysplasia, microphthalmia, and optic nerve malformations [14,15]. To date, at least 334 mutations in PAX6 have been identified . However, the absence of PAX6 mutations in some cases of aniridia implies that mutations in additional genes cannot be excluded [6-10]. This possibility is supported by recent reports: 1) mutations in the forkhead box C1 gene (FOXC1, OMIM 601090) are associated with aniridia in two families [17,18] and 2) aniridia in patients with preserved visual function are not related to PAX6 mutations .
Understanding the mutation spectrum and frequency will not only provide biomarkers for clinical practice but will also represent a fundamental basis for identifying any additional causative genes. The spectrum and frequency of PAX6 mutations in Chinese aniridia patients has not been well identified for the following reasons [20-27]: 1) most reports only involved a single or a limited number of families and 2) mutations were usually detected by cycle sequencing (detection of small variations), in which a larger deletion involving part or all of the gene could not be detected. Cycle sequencing combined with multiplex ligation-dependent probe amplification (MLPA) has been shown to effectively detect small mutations and large deletions in PAX6 . In this study, both cycle sequencing and MLPA were used to detect mutations in the PAX6 gene of 33 Chinese probands with aniridia.
Thirty-three unrelated probands with aniridia participated in this study, including six families previously analyzed by sequencing  and 27 newly selected families. Patients suspected of having Peters anomaly or Rieger syndrome were excluded. All aniridia patients in this study were recruited from our Pediatric and Genetic Eye Clinic at the Eye Hospital of the Zhongshan Ophthalmic Center, Guangzhou, China. Written informed consent that complied with the tenets of the Declaration of Helsinki and following the Guidance of Sample Collection of Human Genetic Diseases (863-Plan) by China’s Ministry of Public Health was obtained from each participant before the study. Genomic DNA was prepared from venous blood.
Thirteen pairs of primers (Table 1) were used to amplify the 14 exons (3 noncoding exons and 11 coding exons) and their adjacent intronic sequences of PAX6 (NCBI human genome build 37.2, NC_000011.9 for gDNA, NM_001604.4 for cDNA, and NP_001595.2 for protein). The PCR products of individual exons for each patient were sequenced using the ABI BigDye Terminator v3.1 Cycle Sequencing Kit (ABI Applied Biosystems, Foster City, CA) and the ABI 3100 Genetic Analyzer (ABI Applied Biosystems) according to the manufacturer’s recommendations. Sequencing results from patients’ sequences and PAX6 consensus sequences from the National Center for Biotechnology Information (NCBI) human genome database (NC_000011.9) were imported into the SeqManII program of the Lasergene package (DNAStar Inc., Madison, WI) and aligned to identify variations. Each mutation was confirmed by bidirectional sequencing. Mutation descriptions followed the nomenclature recommended by the Human Genomic Variation Society (HGVS) .
For patients who were determined not to have a PAX6 mutation based on sequencing analysis, MLPA was used to detect deletions of part or all of PAX6, according to the manufacturer’s instructions (SALSA MLPA Kits P219-B1 PAX6; MRC-Holland bv, Amsterdam, the Netherlands) . Briefly, 100 ng DNA samples were denatured for 5 min at 98 °C and then cooled to 25 °C. Probes were mixed and hybridized with DNA samples at 60 °C overnight and were then reacted with ligase 65 at 54 °C for 15 min, followed by 5 min at 98 °C and then held at 4 °C. Finally, all probes and sample ligations were amplified by PCR using specific carboxyfluorescein (FAM) labeled PCR primers. PCR products were separated by electrophoresis using the ABI PRISM 3100 Analyzer. Data analysis was performed using GeneMarker V1.5 software. A peak area between 0.7 and 1.3 times was considered normal; however, peak areas below 0.7 represent deletions and those above 1.3 represent duplications.
Sequencing of the 14 exons of PAX6 of the 27 probands revealed 12 mutations in 13 patients, including five novel deletion/insertion mutations and seven known point mutations, as follows: c.[65_94del30; 99_105dup7] (p.P22LfsX25), c.101_102insA (p.Q34fsx21), c.177delG (R59SfsX19), c.238_239insGCGA (p.S80fsx12), c.1033–42_1033–26del17insG (splice change), c.1A>G (Initiation codon abolished), c.120C>A (p.C40X), c.718C>T (p.R240X), c.949C>T (p.R317X), c.1062C>A (p.Y354X), c.1183G>A (p.G395R), and c.1268A>T (p.X423LeuextX*15; Table 2, Figure 1 and Figure 2). Of the 12 observed mutations, eight resulted in a premature stop codon. The other four were involved in the splicing acceptor, initial codon, or the stop codon. No putative mutations were detected in the other 14 probands. No variants were detected in the three noncoding exons (exons 1~3).
For the 20 probands in whom PAX6 mutations were not detected by sequencing, including the remaining 14 probands from this study and six probands from our previous study , we detected PAX6 deletions involving multiple exons (exons 1–14, 8–14, or 9–14, respectively) in three probands detected by MLPA (Table 2, Figure 3).
Of the 16 probands with PAX6 mutations, all had congenital nystagmus and foveal dysplasia. Complete aniridia, subtotal aniridia, circumpupillary aplasia, or a full iris in both eyes was recorded in probands 11, 2, 2, and 1, respectively (Table 2). One proband (QT634) had a full iris, but his father harbored the same heterozygous PAX6 mutation and had complete aniridia. Additional ocular abnormalities included lens opacities (eight probands), inferior corneal leukoma (one proband with the missense mutation), and microcornea (one proband). The visual acuity of all probands ranged from 0.1 to 0.3, except for five children who were too young to be evaluated (Table 2). Phenotypic variations in the family harboring the c.1A>G mutation were observed: one proband (QT522) had complete absence of the iris in both eyes, although her mother with the same PAX6 mutation only had iris defects similar to iris coloboma (Figure 4). The patient with the missense mutation (c.1183G>A, p.G395R) had typical aniridia and inferior corneal leukoma.
The mutation frequency of PAX6 in Chinese aniridia patients is similar to that in Caucasian aniridia patients. In this study, PAX6 mutations were identified in 16 of the 33 families tested. When the results of this study are combined with those of our previous study , the PAX6 mutations have been identified in 21 of 38 unrelated patients using cycle sequencing and MLPA. Of the 21 patients, mutations in 18 patients were identified by analyzing PAX6 coding regions using direct sequencing, and mutations in 3 patients were detected using MLPA. For PAX6 mutations in Chinese aniridia patients, the overall mutation detection rates detected with cycle sequencing, MLPA, or both were 47% (18/38), 8% (3/38), and 55% (21/38), respectively. In a similar study of Caucasian aniridia patients , PAX6 mutations were detected in 49% (34/70), 11% (8/70), and 60% (42/70) patients with cycle sequencing, MLPA, or both, respectively. Several other studies have detected aniridia-associated PAX6 mutations in 30% (9/30) of Mexican patients , 56% of Indian patients , 67% (4/6) of Thai patients , 38%–58% (3/8–14/24) of German patients [32,33], 50% (2/4) of Japanese patients , 79% (30/38) of Danish patients , and 83%–94% (10/12–67/71) of British patients [9,36]. The detection of these mutations was based solely on sequence analysis in most studies, but chromosomal analysis was additionally performed in a few studies. These reports demonstrate that while PAX6 mutations were prevalent, they were not detected in all patients with aniridia. One reason that may account for this is the possibility that small variations outside the exons, such as intronic regions , may not be detectable by the techniques used to analyze PAX6. Furthermore, frequent chromosomal rearrangements have been described in aniridia patients previously , which may not be detectable by cycle sequencing and MLPA. It is also possible that there are mutations in other genes which contribute to aniridia given that mutations in FOXC1 are associated with aniridia [17,18] and that no PAX6 mutations were detected in aniridia patients with preserved visual function .
The spectrum of PAX6 mutations in aniridia is similar within both Chinese and Caucasian patient cohorts. The majority of PAX6 mutations reported so far would lead to truncation of encoded proteins (such as nonsense, splicing, insertion, or deletion mutation) and only about 2%–11.7% are missense mutations [38,39]. In one review , 257 aniridia-associated mutations were classified as nonsense mutations (38.9%), splice mutations (13.2%), frame-shifting insertions or deletions (25.3%), in-frame insertions or deletions (6.2%), missense mutations (11.7%), and run-on mutations (4.7%). For the 21 mutations in the Chinese patients analyzed in the present study, these percentages are 33.3%, 14.3%, 19.0%, zero, 9.5%, and 9.5%, with an additional 14.3% being gross deletions of the PAX6 gene. In addition, seven point mutations detected in this study are known mutations, suggesting common mutations. Of the seven, the p.R240X and p.R317X mutations involving CpG dinucleotides are the most common nonsense mutations in PAX6. The p.C40X mutation was detected in one patient in this study and another patient in our previous study . The run-on mutation, X423LeuextX*15, was detected in two unrelated Chinese patients.
In this study, we detected five novel small insertion/deletion mutations, seven known point mutations, and three known gross deletions in 33 unrelated aniridia patients. In this and one of our previous studies , the PAX6 gene was analyzed by cycle sequencing and MLPA in 38 unrelated aniridia patients. However, PAX6 mutations were only detected in 55% (21/38) patients. Further studies of the 17 families without PAX6 mutations may elucidate the molecular basis of aniridia in these families.
The authors thank all patients and family members for their participation. We thank Liying Huang and Lijuan Deng for their excellent technical assistance with MLPA. This study was supported by the National Natural Science Foundation of China (30725044, 30800615) and the Fundamental Research Funds of State Key Lab of Ophthalmology, Sun Yat-sen University.